Next Article in Journal
Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients
Next Article in Special Issue
Sick Leave and Factors Influencing Sick Leave in Adult Patients with Atopic Dermatitis: A Cross-Sectional Study
Previous Article in Journal
Molecular Genetic Markers in Acute Myeloid Leukemia
Previous Article in Special Issue
What Should General Practice Trainees Learn about Atopic Eczema?
Open AccessCommunication

New Developments in Biomarkers for Atopic Dermatitis

Department of Dermatology and Allergology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
Author to whom correspondence should be addressed.
Academic Editors: Sebastien Barbarot and Kim Thomas
J. Clin. Med. 2015, 4(3), 479-487;
Received: 23 December 2014 / Revised: 9 February 2015 / Accepted: 24 February 2015 / Published: 16 March 2015
(This article belongs to the Special Issue Epidemiology and Treatment of Atopic Eczema)
The application of biomarkers in medicine is evolving. Biomarkers do not only give us a better understanding of pathogenesis, but also increase treatment efficacy and safety, further enabling more precise clinical care. This paper focuses on the current use of biomarkers in atopic dermatitis, new developments and future perspectives. Biomarkers can be used for many different purposes, including the objective determination of disease severity, confirmation of clinical diagnosis, and to predict response to treatment. In atopic dermatitis, many biomarkers have been investigated as a marker for disease severity. Currently serum thymus and activation-regulated chemokine (TARC) is the superior biomarker for assessing disease severity. However, we have recently shown that the use of a panel of serum biomarkers is more suitable for assessing disease severity than an individual biomarker. In this overview, we will discuss alternative sources for biomarkers, such as saliva and capillary blood, which can increase the user friendliness of biomarkers in atopic dermatitis (AD). Both methods offer simple, non-invasive and cost effective alternatives to venous blood. This provides great translational and clinical potential. Biomarkers will play an increasingly important role in AD research and personalized medicine. The use of biomarkers will enhance the efficacy of AD treatment by facilitating the individualization of therapy targeting the patients’ specific biological signature and also by providing tools for predicting and monitoring of therapeutic response. View Full-Text
Keywords: atopic dermatitis; eczema; biomarkers; disease severity; stratification; dried blood spots; saliva atopic dermatitis; eczema; biomarkers; disease severity; stratification; dried blood spots; saliva
MDPI and ACS Style

Thijs, J.L.; Van Seggelen, W.; Bruijnzeel-Koomen, C.; De Bruin-Weller, M.; Hijnen, D. New Developments in Biomarkers for Atopic Dermatitis. J. Clin. Med. 2015, 4, 479-487.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop